3.239.4.127
dgid:
enl:
npi:0
Neurology
Trending Topics

US FDA Grants Orphan Drug Designation for Retrotope’s RT001 in the Treatment of Progressive SupraNuclear Palsy (PSP)

Posted on

Retrotope announced that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development granted orphan drug designation for its chemically-modified polyunsaturated fatty acid drug (RT001) for the treatment of Progressive SupraNuclear Palsy (PSP). Physicians collaborating with Retrotope have previously received approval from the FDA’s Division of Neurology Products to test RT001 in Expanded Access trials of three patients having PSP, an orphan neurodegenerative disorder that causes progressive impairment of balance and walking; impaired eye movement, abnormal muscle rigidity; dysarthria; and dysphagia and eventual death.

Read the full press release here.

Source: Retrotope, Inc.
-Advertisement-
Related Articles
Potential Therapy for Rare Neurologic Disease
Apr 06, 2020
TG Therapeutics Announces Data Presentations at the Upcoming American Academy of Neurology 72nd Annual Meeting
Mar 11, 2020
Zynerba Pharmaceuticals Presents Health State Utility Index Data on Severity of Fragile X Syndrome (FXS) and Diagnostic Challenges Faced by Caregivers
Mar 11, 2020
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-